CD33 and acute myeloid leukemia: In vitro and in vivo AML models revealed compelling anti-leukemic efficacy for CLL-1-directed ADC and for the T-cell-engaging bispecific antibody αCLL1-αCD3, which was superior to CD33-directed drugs since CLL-1 spares HSCs [106,107].